Brief: Cellect Biotechnology Receives Approval For U.S. Clinical Trial
Dec 23 (Reuters) - Cellect Biotechnology Ltd APOP.O :
* CELLECT BIOTECHNOLOGY RECEIVES APPROVAL FOR U.S. CLINICAL
TRIAL
* CELLECT - GOT APPROVAL TO BEGIN TRIAL IN U.S. TO EVALUATE
SAFETY, TOLERABILITY OF APOGRAFT TECHNOLOGY FOR HAPLOIDENTICAL
BONE MARROW TRANSPLANTATIONS
Source text for Eikon: ID:nPn6xW08la
Further company coverage: APOP.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Quoin Pharmaceuticals
See all newsQuoin Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
Quoin Pharmaceuticals Ltd expected to post a loss of $1.61 a share - Earnings Preview
NASDAQ RESUMED AT 10:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:06 AM